Nusirt Sciences
Nashville, US · Founded 2012 · Delaware corporation · 2 known investors
NuSirt Sciences develops therapies that activate the sirtuin pathway by combining established pharmaceuticals and natural products to treat cardiometabolic conditions of aging and overnutrition, including fatty liver disease (MAFLD/MASH), obesity, type 2 diabetes, and hypertension. Its lead drug candidate TRIPLN combines L-leucine, metformin, and sildenafil, and it also markets LEUSIX, a dietary supplement for cardiometabolic health and weight management.
Founders & leadership
Nusirt Sciences was founded in 2012 by Michael Zemel.
MZ
Michael ZemelFounder
BC
Barbara CannonExecutive
JC
Joseph C. Cook, Jr.Named on SEC filing
Board
ES
Eric SatzBoard director
VB
Vaughn BrysonBoard director
BL
Brian LadenBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$8.1M disclosed across 3 rounds · 2015–2016
▶$2MraisedDec 2016 · 29 investors · PharmaceuticalsRule 506(b)
▶$2MraisedDec 2016 · 29 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian LadenDirector
- Vaughn BrysonDirector
- Joseph C. Cook, Jr.Executive Officer, Director
- Eric SatzDirector
- Michael ZemelExecutive Officer, Director
- Barbara CannonExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $5K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$4MraisedOct 2015 · 28 investors · PharmaceuticalsRule 506(b)
▶$4MraisedOct 2015 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Vaughn BrysonDirector
- Brian LadenDirector
- Eric SatzDirector
- Michael ZemelExecutive Officer, Director
- Joseph C. Cook, Jr.Executive Officer, Director
- Barbara CannonExecutive Officer
- Offering amount
- $8M
- Amount sold
- $4M
- Minimum investment
- $8.5K
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$2.1MraisedMay 2015 · 26 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedMay 2015 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barbara CannonExecutive Officer
- Brian LadenDirector
- Vaughn BrysonDirector
- Eric SatzDirector
- Joseph C. Cook, Jr.Executive Officer, Director
- Michael ZemelDirector
- Offering amount
- $6M
- Amount sold
- $2.1M
- Minimum investment
- $4.7K
- Proceeds to insiders
- $420K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nusirt Sciences do?
- NuSirt Sciences develops therapies that activate the sirtuin pathway by combining established pharmaceuticals and natural products to treat cardiometabolic conditions of aging and overnutrition, including fatty liver disease (MAFLD/MASH), obesity, type 2 diabetes, and hypertension. Its lead drug candidate TRIPLN combines L-leucine, metformin, and sildenafil, and it also markets LEUSIX, a dietary supplement for cardiometabolic health and weight management.
- Who founded Nusirt Sciences?
- Nusirt Sciences was founded by Michael Zemel in 2012.
- Who are Nusirt Sciences's investors?
- Nusirt Sciences's investors include Hatteras Venture Partners, Mountain Group Capital.
- How much funding has Nusirt Sciences raised?
- Nusirt Sciences has disclosed $8.1M raised across 3 rounds.
- Where is Nusirt Sciences headquartered?
- Nusirt Sciences is headquartered in Nashville, US.